Investigational drug · Phase 2
HRS-1358
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HRS-1358"
First trial start
2024
Aug 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-1358", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Unresectable or Metastatic Breast Cancer
- Advanced Solid Tumors
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-1358" as an intervention, largest first.
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsPivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06555068 · 528 participants (planned) · Start Aug 12, 2024 · Primary completion Dec 2027
Drug: HRS-6209 in Combination with Fulvestrant; HRS-6209 in Combination with HRS-1358 and 9 more · For: Advanced Unresectable or Metastatic Breast Cancer; Advanced Solid Tumors
Sites: Shanghai, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06679036 · 300 participants (planned) · Start Jan 21, 2025 · Primary completion Oct 30, 2026
Drug: HRS-2189; Fluvustat and 3 more · For: Advanced Unresectable or Metastatic Breast Cancer
Sites: Harbin, China; Zhengzhou, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT05628870 · 102 participants (planned) · Start Feb 7, 2023 · Primary completion Jun 2025
Drug: HRS-1358 · For: Breast Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Unresectable or Metastatic Breast Cancer
- HRS-6209Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Advanced Unresectable or Metastatic Breast Cancer of Adults
- HRS-2189Phase 23 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Prostate Cancer
- HRS-9813Phase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors, IPF and PPF
- FluvustatPhase 21 trial
Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.